Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.29 Insider Own7.90% Shs Outstand41.51M Perf Week8.36%
Market Cap1.52B Forward P/E- EPS next Y-3.50 Insider Trans0.05% Shs Float34.86M Perf Month15.52%
Income-177.10M PEG- EPS next Q-1.19 Inst Own65.10% Short Float35.79% Perf Quarter47.05%
Sales1.10M P/S1384.55 EPS this Y-2.40% Inst Trans9.81% Short Ratio10.05 Perf Half Y171.98%
Book/sh4.00 P/B9.17 EPS next Y28.00% ROA-65.10% Target Price39.46 Perf Year65.79%
Cash/sh3.78 P/C9.71 EPS next 5Y-0.20% ROE-78.70% 52W Range11.33 - 36.90 Perf YTD153.56%
Dividend- P/FCF- EPS past 5Y-15.90% ROI-53.10% 52W High-0.57% Beta0.94
Dividend %- Quick Ratio4.70 Sales past 5Y-11.10% Gross Margin- 52W Low223.83% ATR2.05
Employees204 Current Ratio4.70 Sales Q/Q- Oper. Margin- RSI (14)63.51 Volatility7.31% 6.44%
OptionableYes Debt/Eq0.16 EPS Q/Q-18.80% Profit Margin- Rel Volume1.36 Prev Close36.23
ShortableYes LT Debt/Eq0.13 EarningsAug 06 BMO Payout- Avg Volume1.24M Price36.69
Recom2.10 SMA207.58% SMA5013.34% SMA20085.08% Volume1,689,523 Change1.27%
Aug-26-15Reiterated ROTH Capital Buy $50 → $45
Aug-26-15Reiterated ROTH Capital Buy $45 → $50
Aug-24-15Upgrade Piper Jaffray Neutral → Overweight $28 → $48
Aug-07-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
May-22-15Reiterated WBB Securities Strong Buy $25 → $35
May-21-15Downgrade BofA/Merrill Buy → Neutral
May-20-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy $14 → $33
May-20-15Upgrade Canaccord Genuity Hold → Buy $16 → $30
May-20-15Reiterated Wedbush Neutral $16 → $25
May-20-15Reiterated ROTH Capital Buy $22 → $45
May-20-15Reiterated RBC Capital Mkts Sector Perform $15 → $20
May-06-15Upgrade Robert W. Baird Neutral → Outperform $16 → $20
Mar-02-15Reiterated Needham Buy $52 → $38
Jan-23-15Initiated RBC Capital Mkts Sector Perform $15
Nov-26-14Upgrade WBB Securities Buy → Strong Buy $25 → $25
Oct-28-14Downgrade Robert W. Baird Outperform → Neutral $53 → $21
Aug-01-14Initiated Oppenheimer Outperform $45
Jul-29-14Upgrade WBB Securities Speculative Buy → Buy $25
Apr-22-14Reiterated Needham Buy $36 → $52
Apr-22-14Reiterated Deutsche Bank Hold $17 → $35
Aug-27-15 12:45PM  Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews at TheStreet +6.03%
12:00PM  The Duchenne Muscular Dystrophy Race Is On at Motley Fool
Aug-26-15 04:30PM  Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review
10:41AM  Sarepta Upgraded On Promising Muscular-Dystrophy Drug at Investor's Business Daily
Aug-25-15 06:57PM  Sarepta gains after-hours as FDA accepts application for Duchenne drug approval at bizjournals.com
06:22PM  FDA Grants Priority Review to Sarepta Drug at The Wall Street Journal
05:17PM  Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne Muscular Dystrophy for Patients Amenable to Exon 51 Skipping Business Wire
Aug-24-15 11:29AM  Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing
06:42AM  Sarepta Therapeutics upgraded by Piper Jaffray
Aug-21-15 12:40PM  Three Bay State biotechs that bucked the recent sell-off and why at bizjournals.com
08:30AM  Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the Potential Treatment of Duchenne Muscular Dystrophy Business Wire
Aug-20-15 08:53AM  The FDA Is Basically Approving Everything. Here's The Data To Prove It at Forbes
Aug-19-15 04:59PM  Treating Female Sexual Dysfunction (And How To Invest In It)
Aug-14-15 12:01PM  Sarepta Therapeutics Made Investors Millionaires in 2 Years at Investopedia
Aug-12-15 12:30PM  Checkmate Pharma is latest cancer drug firm focused on immune system (BBJ photo gallery) at bizjournals.com
12:02PM  3 Small-Cap Biopharma Stocks I'd Never Short at Motley Fool
08:30AM  Sarepta Therapeutics Announces Formation of Strategic & Scientific Advisory Board Business Wire
Aug-11-15 08:33AM  This Undervalued Biotech Company Just Filed For FDA Approval and No One Noticed
Aug-09-15 08:13PM  10-Q for Sarepta Therapeutics, Inc. at Company Spotlight
Aug-07-15 05:58PM  Sarepta Posts Narrower-than-Expected Loss in Q2, Shares Up - Analyst Blog -6.27%
Aug-06-15 02:27PM  Edited Transcript of SRPT earnings conference call or presentation 6-Aug-15 12:00pm GMT +5.81%
01:12PM  Sarepta CEO: All boys in Duchenne trial still walking after nearly 4 years at bizjournals.com
08:07AM  Sarepta Therapeutics reports 2Q loss
08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:09AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q2 2015 Sarepta Therapeutics Inc Earnings Release - Before Market Open
07:03AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
07:00AM  Sarepta Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Developments Business Wire
Aug-04-15 11:25AM  Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short at TheStreet
Jul-31-15 05:15PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-30-15 08:30AM  Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate Developments on August 6, 2015 Business Wire
Jul-22-15 05:01PM  Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplusĀ® platform Business Wire
Jul-20-15 02:45PM  Short sellers retreat from Sarepta and OvaScience at bizjournals.com
02:10PM  FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs at TheStreet
Jul-17-15 01:33PM  Sarepta makes plans to start late-stage tests of two more Duchenne drugs at bizjournals.com
Jul-16-15 04:12PM  Sarepta Soars on FDA Submission for Duchenne Drug at Bloomberg
Jul-15-15 05:10PM  3 Soaring Clinical-Stage Biotechs, and 1 to Buy at Motley Fool
Jul-13-15 04:05PM  Short-Sellers Betting Against These Biotechs
Jul-08-15 08:03AM  What Propelled Sarepta Therapeutics' Stock 19% Higher in June? at Motley Fool
Jul-06-15 07:10AM  How short sellers threaten innovations that could benefit patients at bizjournals.com
Jul-03-15 10:55AM  Sarepta Therapeutics One Step Closer to Drug Approval at Investopedia
Jul-02-15 05:23PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases
Jul-01-15 02:40PM  Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece at TheStreet
11:29AM  Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog
09:58AM  Sarepta Hires ex-Genzyme Head Henri Termeer as Adviser at The Wall Street Journal
08:30AM  Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company Business Wire
Jun-30-15 05:24PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I +7.98%
05:16PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
04:30PM  Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog
04:25PM  BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog
01:39PM  5 Biotech Stocks On Deck With The FDA
08:55AM  Top Analyst Upgrades and Downgrades: Apollo, Petrobras, Shopify, Fitbit, Sarepta, Lowes and More at 24/7 Wall St.
Jun-29-15 03:50PM  Sarepta CEO: Teamwork has been key to quick progress on Duchenne drug at bizjournals.com -9.85%
03:44PM  The Reason Behind Sarepta Therapeutics Inc.'s Sinking Stock Price at Motley Fool
03:20PM  Sarepta Takes Its Foot off the Gas
02:09PM  Orchid Island Capital Inc (ORC), Sarepta Therapeutics Inc (SRPT) & First Bancorp (FBP) Plunging: Were Hedge Funds Right About These Stocks? at Insider Monkey
01:09PM  Sell The News In Sarepta Therapeutics
10:18AM  BioMarin, Sarepta Muscular Dystrophy Drugs Progress at Investor's Business Daily
07:18AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
07:02AM  Sarepta Submits DMD Drug for FDA Approval Review at TheStreet
07:01AM  Sarepta Therapeutics Secures $40 Million in Debt Financing Business Wire
07:00AM  Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Business Wire
Jun-26-15 06:35PM  BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog
Jun-17-15 01:24PM  SunTrust's 5 Biotech Picks For The Next 6 Months
11:51AM  Five Biotech Stocks for the Next Six Months at Barrons.com
08:20AM  LLTP Shares Attractive On Rolling NDA Submission - 300 Percent in Potential Upside
Jun-09-15 04:25PM  BioMarin Seeks EU Approval for DMD Drug Drisapersen - Analyst Blog
02:41PM  Sarepta flying the flag high and tight
Jun-05-15 05:02AM  Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind at TheStreet +5.07%
Jun-03-15 09:01AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-29-15 05:00PM  Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
01:00PM  Five things you never knew about Sarepta's interim CEO, Ed Kaye at bizjournals.com
May-28-15 02:07PM  These dozen Mass. companies are honed in on drugs for rare diseases (BBJ photo gallery) at bizjournals.com
May-23-15 08:10AM  What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds at Forbes
May-21-15 05:24PM  Biotech stock set to double -7.55%
12:38AM  Sareptas Feast May Not Satisfy at The Wall Street Journal
May-20-15 05:45PM  Stock Pops & Drops: SRPT, PBY, TWTR & FEYE +60.20%
05:14PM  Sarepta's Feast May Not Satisfy at The Wall Street Journal
04:48PM  Analysts See More Upside For Sarepta Therapeutics
03:19PM  6 stocks to watch at MarketWatch
02:53PM  Sarepta Explodes On Monster Volume Following Progress With FDA
12:01PM  Sarepta: Is There Upside After 50% Gain? at Barrons.com
11:50AM  Sarepta to Finish Eteplirsen Regulatory Filing by Mid-15 - Analyst Blog
11:45AM  Sarepta Soars On New Hope For Muscular-Dystrophy Drug at Investor's Business Daily
11:25AM  Sarepta Therapeutics (SRPT) Stock Soars Following Positive Meeting With FDA at TheStreet
11:10AM  How Sarepta Short Interest Is Adding to Its Gains at 24/7 Wall St.
11:07AM  Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying at TheStreet
09:23AM  Cramer's Mad Dash: Regeneron goes higher
09:16AM  Watch These After-Hours Movers
09:06AM  Stock Futures Aim For Mixed Open; Sarepta Soars, Etsy Heads South at Investor's Business Daily
May-19-15 05:46PM  Sarepta shares surge on muscular dystrophy drug filing at MarketWatch
05:38PM  After-hours buzz: Yahoo, Etsy & more at CNBC
05:33PM  Sarepta Shares Surge on Drug Update at The Wall Street Journal
05:17PM  Etsy shares fall after results show surprise loss at MarketWatch
04:42PM  FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug! at TheStreet
04:00PM  Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Todays Pre-NDA Meeting with the FDA Business Wire
May-15-15 01:04PM  SAREPTA THERAPEUTICS, INC. Financials
May-12-15 04:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-10-15 08:11PM  10-Q for Sarepta Therapeutics, Inc. at Company Spotlight
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDSVP & Chief Medical OfficerFeb 27Buy11.828009,4521,311Mar 03 06:48 PM
Christopher Nishan GarabedianPresident and CEOFeb 27Buy11.828009,45229,552Mar 03 06:47 PM